BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

SER

Serina Therapeutics, Inc.
NYSE · Pharmaceutical preparations (SIC 2834) · FY ends 31 Dec

Revenue, quarterly

$0−100.0% year on year
$4M$2M$0−$2M
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 13 Aug 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

3.2%−58.5 pp year on year
100%50%0%
Q4 ’19Q4 ’20Q4 ’21Q4 ’22Q4 ’23
Company filings · 10-K filed 22 Mar 2024 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$23M+281.1% year on year
$30M$20M$10M$0
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 13 Aug 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

−$21M
$10M$0−$10M−$20M−$30M
Q3 ’21Q4 ’22Q1 ’24Q1 ’25Q2 ’26
Company filings · 10-Q filed 13 Aug 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty